The most critical window for recovery after a stroke is measured in weeks, a period when intensive, repetitive movement can rewire the brain. Yet access to that kind of one-on-one, guided therapy is often constrained by a simple shortage of human hands. From a lab at the University of Edinburgh, a team of engineers saw a different kind of hand as the answer: a soft, air-powered robotic glove.
That device is now the centerpiece of Edinburgh-based Bioliberty’s commercial push into the massive and fragmented U.S. post-acute care market. The company’s Lifehub Clinic platform, which launched stateside in May 2025, pairs the wearable ‘Lifeglov’ with interactive software designed to guide patients through upper-limb rehabilitation protocols [HIT Consultant, May 2025]. The bet is that by making high-repetition therapy more accessible and data-rich, they can improve outcomes for the hundreds of thousands of Americans recovering from stroke and other neurological injuries each year.
The Wedge: A Softer Robot
Bioliberty’s approach stands apart from heavier, more rigid exoskeletons often used in research settings. The Lifeglov is a fabric-based device powered by controlled air pressure, designed to gently assist a patient in opening their hand,a fundamental movement lost in many stroke survivors [HIT Consultant, May 2025]. The system calibrates the assistance to an individual’s residual ability, aiming to provide just enough support to complete a movement without taking over.
This softer, more approachable form factor is a deliberate commercial strategy. The hardware is intended for use in inpatient and outpatient clinical settings, not just elite research hospitals. By being relatively lightweight and focusing on a single, critical joint function, Bioliberty aims to fit into existing therapy workflows without demanding extensive new training or floor space.
Building a Data Backbone for Recovery
The glove is only one component. The ‘Lifehub’ is the central control unit and software interface that therapists use to set protocols and monitor progress. The platform is designed to collect detailed data on patient performance,repetitions, range of motion, force,creating a digital record of recovery that is often missing from today’s standard pen-and-paper notes. This functional intelligence, as the company terms it, is meant to help clinicians personalize therapy and demonstrate progress to payors [GlobeNewswire, March 2026].
The company’s recent $13.5 million Series A financing, secured in two tranches through 2026, is squarely aimed at building out these software capabilities and the AI models to interpret the data [Finsmes, November 2026]. The round was led by the Scottish National Investment Bank, which contributed $4 million, signaling strong public-sector belief in the company’s export potential [GlobeNewswire, March 2026].
Traction in a Hard-to-Crack Market
Breaking into U.S. healthcare is a formidable task for any foreign medtech startup, requiring navigations of FDA pathways, reimbursement codes, and entrenched provider relationships. Bioliberty’s early signals suggest a focused commercial strategy is gaining footholds. The company reports its technology is supporting patients in several of the largest post-acute care providers in the U.S., and it has a multicenter partnership with the country’s third-largest rehabilitation provider [GlobeNewswire, March 2026].
Specific named partners include the Sheltering Arms Institute, a physical rehabilitation center, and Tampa General Hospital, whose venture arm, TGH Ventures, joined the Series A extension in November 2026 [Sheltering Arms Institute, 2026] [Finsmes, November 2026]. These are not merely pilot projects; they represent the kind of flagship clinical sites that can drive broader adoption within large health systems.
The founding team, emerging from the University of Edinburgh’s School of Engineering, blends technical depth with growing commercial focus. CEO Rowan Armstrong is a Royal Academy of Engineering Fellow, while co-founder Conan Bradley leads commercial strategy [Company Overview | Bioliberty].
| Founder | Role | Key Background |
|---|---|---|
| Rowan Armstrong | Co-Founder & CEO | Royal Academy of Engineering Fellow; University of Edinburgh engineering graduate. |
| Ross O’Hanlon | Co-Founder | University of Edinburgh engineering graduate; original engineering founder. |
| Conan Bradley | Co-Founder | Leads commercial strategy. |
| Shea Quinn | Co-Founder | Named in company founding announcements. |
The Road Ahead and the Risks
The capital infusion and early partnerships paint an optimistic picture, but the path to widespread adoption is lined with specific, well-understood hurdles in digital health. The company must now execute on a complex set of challenges.
- Clinical validation. While the technology is based on sound rehabilitation principles, broader adoption will require published outcomes data demonstrating superior or more efficient recovery compared to standard care. Peer-reviewed studies are the currency of credibility in this field.
- Reimbursement clarity. Securing consistent insurance reimbursement for both the device and the associated therapy sessions is critical for scalability. This often involves a lengthy process of building evidence for specific CPT codes.
- Integration burden. The promise of data-rich therapy is also a potential pitfall if the software adds administrative load instead of reducing it. smooth integration with electronic health records is a non-negotiable for busy clinics.
The company’s answer to these risks appears to be its partnership model. By working closely with large providers like Sheltering Arms from the development phase, they aim to build a product that fits real-world clinical and financial workflows from the start [Sheltering Arms Institute, 2026].
A Focus on Upper Limb Rehabilitation
For the patient population Bioliberty serves,individuals recovering from stroke, traumatic brain injury, or spinal cord injury,the standard of care for upper extremity rehabilitation remains intensely human-dependent. A therapist manually guides a patient’s arm and hand through motions, counts repetitions, and makes subjective assessments of progress. It is effective but resource-limited, often capping the amount of practice a patient can receive. The Lifeglov and Lifehub Clinic represent an attempt to augment that human effort, not replace it, by providing a tool that can extend therapeutic engagement and objectify the measurement of recovery.
The next twelve months will be telling. With its Series A closed, the focus will shift from fundraising to commercial execution: expanding deployments within existing partner networks, pursuing the crucial clinical publications, and navigating the U.S. regulatory and reimbursement landscape. For a company betting on a softer, smarter approach to one of medicine’s oldest challenges, the real work of proving its grip is just beginning.
Sources
- [GlobeNewswire, March 2026] Bioliberty Raises $10.2 million to Build Functional Intelligence Capabilities for Post-Acute Care | https://www.globenewswire.com/news-release/2026/03/19/3258693/0/en/bioliberty-raises-10-2-million-to-build-functional-intelligence-capabilities-for-post-acute-care.html
- [Finsmes, November 2026] Bioliberty Raises Additional $3.3M in Series A Funding | https://www.finsmes.com/2026/11/bioliberty-raises-additional-3-3m-in-series-a-funding.html
- [HIT Consultant, May 2025] Article on Bioliberty's Lifeglov | https://hitconsultant.net/2025/05/19/bioliberty-lifehub-clinic-launch/
- [Sheltering Arms Institute, 2026] Bioliberty Lifehub Clinic Archives - Sheltering Arms Institute | https://shelteringarmsinstitute.com/tag/bioliberty-lifehub-clinic/
- [Company Overview | Bioliberty] Company Overview | https://www.bioliberty.com/
- [University of Edinburgh / Edinburgh Innovations, 2026] Bioliberty secures £7.7m to accelerate product development and international growth | https://eng.ed.ac.uk/about/news/20260323/bioliberty-secures-ps77m-to-accelerate-product-development-and-international